RBNC THERAPEUTICS, INC.Letter Agreement • September 27th, 2023 • Amgen Inc • Biological products, (no disgnostic substances)
Reference is made to (i) that certain Research Collaboration and License Agreement by and between Amgen and the Company, dated as of the date hereof (the “Research and Collaboration Agreement”), (ii) that certain Exclusive License Agreement by and between Amgen and the Company, dated as of the date hereof related to Amgen’s Ckld program (the “Ckld License Agreement”), (iii) that certain Exclusive License Agreement by and between Amgen and the Company, dated as of the date hereof related to Amgen’s GCase program (the “GCase License Agreement” and together with the Ckl d License Agreement, the “License Agreements”), (iv) that certain Stock Issuance Agreement (the “Stock Issuance Agreement”) pursuant to which the Company is issuing shares of its Series A-2 Preferred Stock, par value $0.0001 per share (the “Series A-2 Preferred Stock”) to Amgen in consideration of the rights and obligations under the Research and Collaboration Agreement and the License Agreements, (v) that certain Series A
September 22, 2022 Neumora Therapeutics, Inc. Watertown, Massachusetts 02472 ATTENTION: Chief Executive Officer Re: Amendment to Letter Agreement Ladies and Gentlemen:Letter Agreement • September 27th, 2023 • Amgen Inc • Biological products, (no disgnostic substances)
Reference is made to that certain Letter Agreement, dated as of September 10, 2021, by and between Amgen Inc. (“Amgen”) and Neumora Therapeutics, Inc. (f/k/a RBNC Therapeutics, Inc.; the “Company”), regarding the acquisition of shares of Series A-2 Preferred Stock by Amgen of RBNC Therapeutics, Inc. Capitalized terms not otherwise defined herein shall have their respective meanings in the Letter Agreement.
